Pregnancy and lactation

(229) A national population cohort study of congenital abnormalities following SARS-CoV-2 infection and COVID-19 vaccination during pregnancy

(230) A Population-Based Cohort Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP): Rationale, Design, and Baseline Characteristics

(231) A Target Trial of Pre-conception Switch from a Legacy Medication to a New Medication – An Application to Antiretroviral Therapy and Birth Outcomes

(232) Addressing Over-Representation of Early Pregnancy Outcomes in Database Pregnancy Safety Studies

(233) Algorithms to identify major congenital malformations in routinely collected healthcare databases: A systematic literature review

(234) Analysis of Medicinal Product Utilization Data in the FDA Sentinel System to Inform the Development of a Pregnancy Safety Study Framework

(235) Analysis of Postapproval Pregnancy Safety Studies Associated with FDA Approved Products

(236) Apgar-5 scores variability and associated pregnancy outcomes among hospitalized women: Insights from national linked Brazilian secondary databases

(237) Application of a direct-to-participant EMR data collection platform for pregnancy registries

(238) Assessing the Credibility of Causal Effects: A Critical Analysis of Observational Studies on Pregnancy Drug Use and Congenital Malformations

(239) Association Between Levothyroxine Supplementation for Hypothyroidism in Late Pregnancy and Risk of Preterm Delivery

(240) Association Between Maternal Anticholinergic Burden During Pregnancy and the Risk of Autism Spectrum Disorder: A Population-Based Cohort Study in Taiwan

(241) Association of First Trimester Macrolide Use With Congenital Malformations in the Offspring

(242) Association of prenatal antiseizure medication exposure with risk of neurodevelopmental disorders in children

(243) Associations Between Chronic Diseases and Treatments During Lactation and Maternal Mental Health

(244) Associations between diphenhydramine and specific birth defects stratified by imputed indication, National Birth Defects Prevention Study and Birth Defects Study to Evaluate Pregnancy exposureS

(245) Benefit-Risk Assessment of Herbal Medicines Used During Pregnancy and Lactation: A Descriptive Study of Registered Herbal Medicines in Bulgaria

(246) Changes in the Use of Carbamazepine Before, During and After Pregnancy: A Nationwide Study in France between 2013 and 2021

(247) Characterization of Pregnancy in Women of Childbearing Potential with ASCVD or Likely Familial Hypercholesterolemia: US Claims Analysis

(248) Cohort event monitoring of COVID-19 vaccine safety using patient-reported outcomes in pregnant women.

(249) Comparator Cohort Selection: a Review of Prospective Pregnancy Registries for Multiple Sclerosis (MS) Products

(250) Comparison of Diagnoses Code Profile and Major Congenital Malformation (MCM) Prevalence across US and EU MCM Classification Systems

(251) Comprehensive evaluation of algorithm demonstrates robust performance identifying pregnancy cases in VigiBase

(252) Covid19 Vaccination During Pregnancy: a Descriptive Study of Uptake and Safety for Mothers and Infants Using the Nationwide French National Health System

(253) COVID-19 vaccination rate among pregnant women in France: a nationwide study

(255) Disparities in asthma severity and treatment during pregnancy: description of the Slone Birth Defects Study data

(256) Effect of Tumor Necrosis Factor Inhibitor Use During Pregnancy on Gestational Diabetes Mellitus Among Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study

(257) Effectiveness of Awareness/Recruitment Activities for Pregnancy Registries

(258) Enhanced pharmacovigilance reporting using PRIM: conditions to make it an alternative to traditional pregnancy registry

(259) A Multi-Source Approach to Pregnancy and Lactation Evidence Generation in Multiple Sclerosis: The Ocrelizumab Example

(260) A systematic review of gabapentinoids use during pregnancy and effects on pregnancy and childhood outcomes: an IMI ConcePTION study

(260) Evaluation of Digital Data collection Methods in a Prospective Pregnancy Registry for a Migraine Product with Both Acute and Preventive Indications

(261) Exposure to antibiotics during pregnancy or early infancy and the risk of autoimmune disease in children: A nationwide cohort study with sibling matched analysis

(262) Antidepressant and Psychotherapy Initiation Among Patients with New Episodes of Depression During Pregnancy

(262) Exposure to potentially harmful drugs during pregnancy in women with rheumatoid arthritis – a German claims data analysis

(263) Antiseizure medication use during pregnancy and the Risk of adverse neonatal birth outcomes in two Canadian provinces

(264) Cardiac Autonomic Stress Response in 6- and 12-Year-Old Children After Prenatal Selective Serotonin Reuptake Inhibitor Medication Exposure: A Cohort Study

(264) Fetal and Neonatal Alloimmune Thrombocytopenia: Systematic Literature Review and Challenges Encountered

(265) Characteristics and Adverse Postpartum Psychiatric Outcomes in Women With Bipolar Disorder Who Discontinue Lithium During Pregnancy: A Swedish Cohort Study

(265) Finding the Forest in the TreeScan: A Big Data Driven Approach to Screening Drug Use in Pregnancy

(266) Characteristics and Depression Severity Among Pregnant Women by Antidepressant Use During Pregnancy

(266) First trimester tetracycline use and risk of major congenital malformations: A cohort study

(267) Characteristics of perinatal depression screening and trend over time in a commercial, US-based administrative claims database

(268) Comparative safety of prenatal exposure to buprenorphine versus methadone with regards to adverse neurodevelopmental outcomes

(268) Human Breastmilk Microbiome in Individuals with Hypothyroidism Treated with Levothyroxine Compared to Healthy Controls

(269) Comparison of antidepressant use in normal-age and late-age pregnancies

(269) Identification of Maternal Characteristics, Pregnancy Characteristics and Pregnancy Outcomes through Linked Maternal and Infant Databases in Brazil

(270) Concomitant Periconceptional Opioid Medication, Alcohol, and Tobacco Use

(271) Discontinuation patterns of antipsychotics in pregnant women: A cohort study from South Korea

(271) Improving Access to HIV-Related Healthcare, including Treatment and Pre-Exposure Prophylaxis (PrEP) in Zimbabwe Among Young Mothers Living with HIV

(272) Emergency Department Visits due to Monoclonal Antibody Adverse Events—United States, 2004–2020

(272) Incidence of pregnancy among publicly and commercially insured childbearing-age women with warfarin treatment

(273) Gabapentin in Pregnancy and Birth Outcomes: a Population-based Prevalence Study in Nordic Countries (EUPAS38620)

(273) Is Hypothyroidism in Pregnancy Overtreated? A Retrospective Cohort Study from Bulgaria

(274) Gabapentin Use During Pregnancy and the Risk of Adverse Neonatal Birth Outcomes in two Canadian provinces

(274) Language and racial disparities in initial COVID-19 vaccination during pregnancy

(275) Gabapentinoids exposure in early pregnancy and risk of congenital anomalies: an IMI ConcePTION European case-malformed control study

(275) Linkage of Mother and Infant Records using Commercial Claims Data within the Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative

(276) Intensity and duration antidepressant exposure in pregnancy and childhood growth trajectories: results from the Norwegian Mother, Father and Child Cohort Study

(276) Linkage of Pregnancies and Infants to Potential Male Parents in a Health Insurance Claims Database

(277) Lower Rates of Initiation of Breastfeeding and Exclusive breastfeeding in Women Treated with Chronically Used Anti-inflammatory Medications

(277) Maternal Mental Health in Focus: Real-World Data on Antidepressant Use. A Cohort Study in Catalonia.

(278) Maternal and Infant Outcomes Following Infliximab Exposure During Pregnancy

(278) Maternal opioid use during breastfeeding and the risk of adverse infant outcomes: A nationwide cohort study among 4 million mother-child dyads

(279) Maternal outcomes in women receiving COVID-19 vaccination during pregnancy compared with influenza vaccines in spontaneous reporting databases

(279) Opioid Use in Pregnancy in Women with Disabilities

(280) Miscarriage Preventing Herbal Medicines and the Risk of Birth Defects: A Population-Based Cohort Study of 195,824 Pregnancies

(280) Pregnancy and Fetal Outcomes after Maternal Exposure to Glatiramer Acetate – an Updated Analysis

(281) Neonatal Intensive Care Unit Services among Commercially Insured Infants in the United States, 2016 – 2023

(281) Progress Towards Enrollment in a US Pregnancy Registry for Galcanezumab and Lasmiditan

(282) Opioid Analgesic and Antidepressant Use During Pregnancy and the Risk of Spontaneous Preterm Birth: A Nested Case-Control Study

(282) Reason for gabapentinoids prescribing in pregnancy: results from five European countries. A contribution from the IMI ConcePTION project

(283) Opioid Toxicity in the Year After Pregnancy Among Women with Disabilities

(283) Trends in antidepressant use during early pregnancy in Germany between 2005 and 2020

(284) Oral Antihypertensives in Hypertensive Pregnancy and the Association with Fetal Growth: a Population-Based Cohort Study

(285) Outcome-Anchored Cohorts to Prevent Pregnancy Study Pitfalls: A Conceptual Approach for Preventing Bias in Post-Approval Pregnancy Safety Studies

(287) Paternal exposure to valproate and the risk of Neuro-Developmental Disorders in offspring: a population-based cohort study in Denmark, Norway and Sweden

(288) Patterns of Prescribed and Dispensed Medicines among Non-Hospitalized Pregnant women with COVID-19: a Prospective Meta-analysis pooling findings from Healthcare Databases in Europe and North America

(291) Postpartum Treatment Initiation among Pregnancies Diagnosed with Hepatitis C between 2016-2021 using the United States Commercial Claims Data

(292) Prediction of Hemolytic Disease of the Fetus and Newborn in neonates from alloimmunized pregnancies

(293) Predictors for correct vitamin D intake among pregnant women in the Netherlands

(294) Pregnancies and prescription drug use during pregnancy in women of childbearing potential with chronic spontaneous urticaria in the United States – A descriptive analysis

(296) Pregnancy and infant outcomes in gestationally-diagnosed breast cancer: A pilot study in Finland and Norway from the IMI ConcePTION project

(297) Pregnancy and Pain Outcomes When Elagolix and Hormonal Contraceptives are Used Concomitantly: A Prospective Cohort Study Using a Health Insurance Claims Database

(299) Pregnant persons' perceptions of RSV vaccination during pregnancy

(300) Prenatal exposure to antiseizure medications and neurodevelopmental disorders: Children population-based cohort from the Quebec Pregnancy/Child Cohort

(302) Prenatal syphilis in the US: characterizing screening and treatment during pregnancy in publicly and commercially insured individuals

(303) Prevalence of major congenital malformations in France between 2010 and 2021: estimates among the 9 millions children and foetuses of the EPI-MERES register and relevance for perinatal pharmacoepidemiology

(304) Prevalence of medication use for COVID-19 treatment in pregnancy: a two-stage individual patient data meta-analysis combining international registries.

(305) Prevalence of Selected Health Conditions among Individuals with Childbearing Potential to Inform the Development of the Pregnancy Safety Study Framework

(306) Recreational drug use in Pregnancy: An observational study

(307) Replicating a Published Real-World Evidence Study to Analyze Maternal Delivery Complications Using Electronic Medical Records from Community Hospitals

(308) Reproductive safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) after maternal exposure in early pregnancy: a comparative ENTIS cohort study

(309) Retrospective Application of the FDA Preliminary Pregnancy Safety Studies Framework to an Ongoing Pregnancy-Related Commitment

(310) Risk of congenital ocular anomaly in EUROmediCAT: Assessment of the Potential Risk of Taking Medications during Pregnancy in Europe.

(311) Risk of Neonatal and Maternal Adverse Events of Oral Anti-hypertensive Medications Used in Pregnancy: Evidence Synthesis from a Disproportionality Analysis

(313) Specific congenital anomalies associated with maternal Multiple Sclerosis: A ConcePTION European case-malformed control study

(314) The association between COVID-19 vaccination during pregnancy and neonatal health outcomes

(315) The BELpREG Registry on Perinatal Medication Exposure and Mother-Infant Outcomes: Preliminary Insights into this unique Pregnancy Cohort in Belgium

(316) The IMEDS Distributed Database Network and Pregnancy Studies

(317) The Impact of the Mother-Infant Linkage Process in US Health Insurance Claims Data on the Representativeness of the Infant Sample

(318) The occurrence of specific congenital anomalies associated with maternal Systemic Lupus Erythematosus: A ConcePTION Case-malformed control study in EUROmediCAT

(319) The PregVal Project. A Population-based Cohort to Assess Drug Use and Safety During Pregnancy.

(321) Uptake of prescription smoking cessation pharmacotherapies during pregnancy: a population-based utilisation study across Australia, New Zealand, Norway, and Sweden

(322) US Claims Adaptation of the European Concerted Action on Congenital Anomalies and Twins (EUROCAT) Guide 1.5 for Use in Pregnancy Studies

(323) Use of healthcare administrative claims data in observational studies of antirheumatic drug effects on pregnancy outcomes: a scoping review

(325) Use of population-based real world data sources and disease specific registries to conduct post approval pregnancy safety studies for a biologic indicated for a complex, uncommon indication - challenges and opportunities

(326) Use of the novel antiviral PAXLOVID for COVID-19 during pregnancy: methodological considerations for defining the baseline period across treated and untreated comparator cohorts

(329) Using Real-World Data to Quantify the Rate of Unintended Pregnancies and Specified Adverse Events in Women Prescribed Oral Levonorgestrel 30µg or Levonorgestrel Implant